MorphoSys Says Primary Goal Of Re-MIND Study Has Been Met

(RTTNews) - MorphoSys AG (MOR) Tuesday said the primary endpoint was met of a real-world data study demonstrating clinical superiority of the combination of tafasitamab and lenalidomide compared to lenalidomide alone.

According to the company, the study collected data from 490 non-transplant eligible patients with relapsed/ refractory diffuse large B cell lymphoma who had received lenalidomide monotherapy in the U.S. and the EU in a real-world setting.

As a result, 76 eligible patients were identified and matched 1:1 to 76 of 80 L-MIND patients based on important baseline characteristics.

The primary endpoint of the study has been met and shows a statistically significant superior best ORR of the tafasitamab/lenalidomide combination compared to lenalidomide monotherapy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.